ReproCELL
ReproCELL Incorporated is primarily engaged in the development of stem cell technologies. The Company operates its business in two segments. The IPS Cell segment deals with regenerative medicine focused on Human ES (embryonic stem) cells and human iPS (induced pluripotent stem) cells. This segment manufactures research reagents used in human ES / iPS cell research, such as culture fluid, peeling liquid, frozen preservation solution, coating agents and antibody. The Clinical Testing segment clinical testing services that is required by hematopoietic stem cell transplantation and organ transplantation. On February 10, 2014, it established a Kanagawa-based wholly owned subsidiary. On June 30, 2014, it acquired 85.2% interests in Reinnervate Limited, a UK-based company. On July 1, 2014, it fully acquired Reinnervate Limited. In July, 2014, it acquired BioServe Biotechnologies, Ltd. On September 2, 2014, it completed the acquisition of BioServe Biotechnologies, Ltd.
Symic Biomedical is a developer of matrix regulator therapeutics designed to affect matrix degradation and structure. The company's therapeutics bind to targets in the matrix, damaged in response to injury or because of disease, to inhibit pathological inflammatory responses, enabling clinicians to investigate applications in the areas of fibrosis, oncology and diseases of the central nervous system.
Founded in Hyderabad in 2002, BioServe-India was the first company to provide DNA synthesis, DNA sequencing, and related services in India. BioServe India brings Indian scientists, pharmaceutical companies, and research institutes a 'Biomaterial to Data' model that offers a full suite of molecular services and research tools to accelerate breakthroughs in genetics, drug discovery, biomarker research, and molecular diagnostics. Our services at BioServe-India include Food Pathogen Testing and testing for Genetically Modified Organisms in finished products. BioServe-India is a DSIR recognized laboratory with ISO9001-2008 and NABL accreditation. BioServe-India’s customers include nearly every ICMR and CSIR institute and several major pharmaceutical and biotechnology companies, as well as top industry and academic researchers.
Kringle Pharma, Inc. is a biopharmaceutical company focused on the research and development of hepatocyte growth factor (HGF) protein medicines and NK4 molecules. Established in 2001 and headquartered in Japan, the company aims to harness the regenerative properties of HGF for various medical conditions, including acute spinal cord injury, amyotrophic lateral sclerosis (ALS), acute kidney injury, and vocal fold scarring. In addition to HGF, Kringle Pharma develops NK4, which acts as an antagonist to HGF and exhibits anti-cancer properties by inhibiting tumor cell invasion and metastasis. The company's product pipeline includes recombinant human HGF for treating acute renal failure, skin ulcers, and central nervous system disorders, as well as NK4 and NK4 gene therapies for cancer treatment.
Biopta Ltd is a human tissue-based contract research organisation. Biopta offers services using ethically donated residual human tissue from surgery as a test system for new pharmaceutical compounds.
ReInnervate Limited, a biotechnology company, engages in the development of enabling technologies that facilitate research into cell growth and function in vitro, primarily in the field of stem cell biology. Its technologies control the differentiation of stem cells and the formation of specific tissue types, as well as offers tools to develop diagnostics and treatments for neuro-degenerative diseases. The company was founded in 2002 and is based in Durham, the United Kingdom.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.